Market Size of Global Sacral Nerve Stimulation Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 5.50 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Sacral Nerve Stimulation Market Analysis
The Sacral Nerve Stimulation Market is expected to register a CAGR of 5.5% over the forecast period (2022-2027).
The impact of the COVID-19 outbreak on the sacral nerve stimulation market is expected to be significant, as most non-COVID treatment services were disrupted to reserve the healthcare infrastructure for COVID-19-infected patients and minimize the risk of transmission of the SARS-CoV-2 virus. According to a study published in the British Journal of Surgery in May 2020, due to 12 weeks of peak disruption in hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed and reviews suggest that between 16% to 20% of these surgical procedures constitute of sacral nerve surgical procedures, impacting the sacral nerve stimulation market. Additionally, according to a research study by Jeremy Yuen-Chun Teoh et al., titled " A Global Survey on the Impact of COVID-19 on Urological Services" (2020), globally, the outpatient clinics for female urinary incontinence, benign prostatic hyperplasia, infertility, and sexual medicine, benign scrotal conditions, renal stone, and bladder stone were the most affected by the pandemic. Also, a delay of more than eight weeks for urological services was reported for 28% of all outpatient clinics, 30% of all outpatient investigations and procedures, and 31% of all urological surgeries during the COVID-19 pandemic. Hence, given the facts, the studied market is predicted to be negatively impacted due to the COVID-19 pandemic.
The rising prevalence of overactive bladder conditions and the increasing incidence of urge incontinence, such as urinary tract infection (UTI), are the major drivers for the growth of the market studied. Also, the growing incidence of fecal incontinence and the availability of medical reimbursements are some other factors fueling the market growth. For instance, in 2021, an article titled, 'Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories' reported that globally, urinary tract infection (UTI) was attributed to the most disability-adjusted life-years (DALYs) among the three diseases reported in the article and about 68.89% of individuals were infected with urinary tract infections (UTI) globally during the study period.
Furthermore, the prevalence of urinary incontinence is more in women than in men. For instance, according to a research study by Sedighe Batman et al., published in the BMC Geriatrics Journal in March 2021, the highest prevalence of urinary incontinence was reported to be in older adult women in Asia (45.1%). Some factors influencing the incidence of urinary incontinence in older women are age, obesity, diabetes, hypertension, and smoking. Thus, the growing target patient pool may drive the demand for treatment and promote the sacral nerve stimulation market in the coming years. Furthermore, the rising geriatric population globally is driving the market.
Thus, increasing aging along with growing research investments, and technological advancements associated with the development of novel medical devices are expected to drive the market. However, health risks associated with the devices are expected to slow down the market over the forecast period.